生物医药公司荣昌生物(09995)今日股价大涨17.46%,引发市场关注。分析人士指出,公司今年前三季度业绩超预期是主要原因,尤其第三季度亏损环比大幅收窄。
荣昌生物2024年前三季度营业收入约12.09亿元,同比大增57.1%,主要由于公司旗舰产品泰它西普和维迪西妥单抗销售持续向好,带动收入攀升。而归属于上市公司股东的净亏损约10.71亿元,同比扩大3.96%,但第三季度亏损2.9亿元,较第二季度环比减少逾32%,显著好于预期。这主要得益于研发费用管控同比大幅改善。
多家券商给予荣昌生物较为看好的评级。浦银国际认为,未来一年内荣昌生物两大产品有望在国内进一步扩大适应症获批范围、海外注册临床继续推进。看好公司长期成长前景。交银国际亦指出,公司现金流充足,足以支持近期运营。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.